Repurposing FDA-approved drugs as potential PARP inhibitors

被引：0
|
作者：
Eznarriaga, Maria [1 ]
Rahman, Taufiq [1 ]
机构：
[1] Univ Cambridge, Cambridge, England
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2020年 / 177卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P070
引用
收藏
页码：2516 / 2516
页数：1
相关论文
共 50 条
  • [41] Repurposing of FDA-approved drugs as inhibitors of sterol C-24 methyltransferase of Leishmania donovani to fight against leishmaniasis
    Tabrez, Shams
    Rahman, Fazlur
    Ali, Rahat
    Muhammad, Fida
    Alshehri, Bader Mohammed
    Alaidarous, Mohammed A.
    Banawas, Saeed
    Bin Dukhyil, Abdul Aziz
    Rub, Abdur
    DRUG DEVELOPMENT RESEARCH, 2021, 82 (08) : 1154 - 1161
  • [42] A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles
    Battah, Basem
    Chemi, Giulia
    Butini, Stefania
    Campiani, Giuseppe
    Brogi, Simone
    Delogu, Giovanni
    Gemma, Sandra
    MOLECULES, 2019, 24 (23):
  • [43] Computational screening of FDA-approved drugs to identify potential aromatase receptor inhibitors for polycystic ovary syndrome
    Koohnavard, Fahimeh
    Ahmadi, Khadijeh
    Eftekhar, Ebrahim
    Edalatmanesh, Mohammad Amin
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (24): : 15507 - 15519
  • [44] Potential Impacts of transitioning FDA-approved radioactive drugs to medical devices
    Hung, Joseph
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [45] Repurposing FDA-approved drugs to treat chemical weapon toxicities: Interactive case studies for trainees
    Aleksunes, Lauren M.
    Gray, Joshua P.
    Meshanni, Jaclynn
    Laskin, Jeffrey D.
    Laskin, Debra L.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [46] Repurposing of FDA-approved Sesquiterpene Lactone Antimalarial drugs for Mitochondria-targeted Cancer Therapy
    Varmazyad, Mahboubeh
    Kalen, Amanda
    Sarsour, Ehab
    Pigge, F.
    Schultz, Michael
    Goswami, Prabhat
    FREE RADICAL BIOLOGY AND MEDICINE, 2019, 145 : S79 - S79
  • [47] Repurposing FDA-approved drugs to inhibit IL-33 mediated mast cell function
    Long, Dionna L.
    Burchett, Jason R.
    Ryan, John J.
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [48] Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization
    Kulkarni, Ameya S.
    Aleksic, Sandra
    Berger, David M.
    Sierra, Felipe
    Kuchel, George A.
    Barzilai, Nir
    AGING CELL, 2022, 21 (04)
  • [49] A comprehensive computational framework for repurposing FDA-approved drugs to interfere with Pseudomonas aeruginosa quorum sensing
    Terali, K.
    Guran, M.
    Perez Sanchez, H.
    JOURNAL OF BIOTECHNOLOGY, 2019, 305 : S22 - S22
  • [50] Repurposing FDA-approved drugs as NLRP3 inhibitors against inflammatory diseases: machine learning and molecular simulation approaches
    Agarwal, Vipul
    Haldhar, Rajesh
    Hirad, Abdurahman Hajinur
    Ahmed, Bilal
    Han, Sang Beom
    Gupta, Anugya
    Raj, Vinit
    Lee, Sangkil
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024,
12345